Silexion Raises $1M Through Warrant Exercise and Issues New Series C/D Warrants
Silexion Therapeutics has exercised warrants to sell 1,995,092 shares at $0.50 per share, raising approximately $1 million in gross proceeds. The company will issue new unregistered Series C warrants for 2,045,000 shares and Series D warrants for 1,945,184 shares exercisable after shareholder approval.
1. Warrant Exercise and Gross Proceeds
In May 2026, Silexion Therapeutics completed the immediate exercise of warrants to purchase 1,995,092 ordinary shares at $0.50 per share, generating approximately $1 million in gross proceeds before placement agent fees and offering expenses.
2. Issuance of New Series C and D Warrants
In consideration for the cash exercise, the company will issue unregistered Series C warrants to purchase up to 2,045,000 ordinary shares and unregistered Series D warrants to purchase up to 1,945,184 ordinary shares, both with a $0.50 exercise price and subject to shareholder approval and registration requirements.
3. Use of Proceeds and Closing Conditions
Net proceeds are intended for general corporate working capital, and the offering is expected to close on or around May 18, 2026, subject to customary closing conditions and satisfaction of effective resale registration statements.